Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Braz. j. med. biol. res ; 48(7): 610-615, 07/2015. tab, graf
Article Dans Anglais | LILACS | ID: lil-751341

Résumé

Li-Fraumeni syndrome (LFS) is a rare, autosomal dominant, hereditary cancer predisposition disorder. In Brazil, the p.R337H TP53 founder mutation causes the variant form of LFS, Li-Fraumeni-like syndrome. The occurrence of cancer and age of disease onset are known to vary, even in patients carrying the same mutation, and several mechanisms such as genetic and epigenetic alterations may be involved in this variability. However, the extent of involvement of such events has not been clarified. It is well established that p53 regulates several pathways, including the thymine DNA glycosylase (TDG) pathway, which regulates the DNA methylation of several genes. This study aimed to identify the DNA methylation pattern of genes potentially related to the TDG pathway (CDKN2A, FOXA1, HOXD8, OCT4, SOX2, and SOX17) in 30 patients with germline TP53 mutations, 10 patients with wild-type TP53, and 10 healthy individuals. We also evaluated TDG expression in patients with adrenocortical tumors (ADR) with and without the p.R337H TP53 mutation. Gene methylation patterns of peripheral blood DNA samples assessed by pyrosequencing revealed no significant differences between the three groups. However, increased TDG expression was observed by quantitative reverse transcription PCR in p.R337H carriers with ADR. Considering the rarity of this phenotype and the relevance of these findings, further studies using a larger sample set are necessary to confirm our results.


Sujets)
Humains , Antirhumatismaux/effets indésirables , Polyarthrite rhumatoïde/traitement médicamenteux , Produits biologiques/effets indésirables , Antirhumatismaux/usage thérapeutique , Produits biologiques/usage thérapeutique , Médecine factuelle/méthodes , Tumeurs/induit chimiquement , Infections opportunistes/induit chimiquement , Guides de bonnes pratiques cliniques comme sujet , Appréciation des risques/méthodes , Facteur de nécrose tumorale alpha/antagonistes et inhibiteurs
SÉLECTION CITATIONS
Détails de la recherche